Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism

Antithrombotic Therapy for VTE Disease

(2016) Clive Kearon et al.   CHEST

Prognostic Accuracy of Clinical Prediction Rules for Early Post-Pulmonary Embolism All-Cause Mortality

(2015) Christine G. Kohn et al.   CHEST

Derivation and validation of the In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) prediction rule

(2015) Craig I. Coleman et al.   CURRENT MEDICAL RESEARCH AND OPINION

Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism

(2014) Bonno van Bellen et al.   CURRENT MEDICAL RESEARCH AND OPINION

Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?

(2014) François Laliberté et al.   CURRENT MEDICAL RESEARCH AND OPINION

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

(2014)   EUROPEAN HEART JOURNAL

Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program

(2014) Brahim K. Bookhart et al.   JOURNAL OF MEDICAL ECONOMICS

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

(2013) François Laliberté et al.   CURRENT MEDICAL RESEARCH AND OPINION

Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism

(2012) W. Zondag et al.   THROMBOSIS AND HAEMOSTASIS

Simplification of the Pulmonary Embolism Severity Index for Prognostication in Patients With Acute Symptomatic Pulmonary Embolism

(2010) David Jiménez   ARCHIVES OF INTERNAL MEDICINE